Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours.
ACTRN 12623000959673 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forward